NCT00706862View on ClinicalTrials.gov

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

June 30, 2015

Study Completion Date

March 31, 2016

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Talactoferrin

Oral, 1.5 grams twice per day

DRUG

Placebo

Oral, twice per day

Trial Locations (6)

10467

RECRUITING

Montefiore Medical Center, The Bronx

27710

RECRUITING

Duke University Medical Center, Durham

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

37404

RECRUITING

Chattanooga Oncology and Hematology Associates, Chattanooga

60612

WITHDRAWN

Rush University Medical Center, Chicago

91010

RECRUITING

City of Hope, Duarte

Sponsors

Lead Sponsor

Agennix
All Listed Sponsors
lead

Agennix

INDUSTRY

NCT00706862 - Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter